Drug Trial News

RSS

CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital.

20 Nov 2024

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

New nasal spray form of bumetanide shows promise for heart failure treatment

A new nasal spray form of the medication bumetanide may reduce the tissue swelling caused by heart failure as effectively as the standard oral and intravenous formulations of the medication, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

19 Nov 2024

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Results from a randomized phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months.

19 Nov 2024

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

Daily tablet shows promise in treating achondroplasia in children

A promising daily tablet is effective at increasing height and improving proportional limb growth in children with achondroplasia, the most common form of dwarfism, according to a new study.

18 Nov 2024

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at the American Heart Association's Scientific Sessions 2024.

18 Nov 2024

New clinical trial offers hope for patients with rare immune disease IgG4-RD

A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4-RD)

18 Nov 2024

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.

14 Nov 2024

Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease

An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.

14 Nov 2024

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.

14 Nov 2024

VANCE trial marks milestone in t cell therapy for solid tumors

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

11 Nov 2024

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

8 Nov 2024

Recruitment underway for a clinical trial testing new vaccine against respiratory viruses

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.

8 Nov 2024

Combination therapy shows promising results in treating stage 3 melanoma

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute (NCI).

1 Nov 2024

Two topical treatments show similar benefits for photoaging of the hands

Topically applied products containing human platelet extract or vitamin C provide similar improvements in age spots (photoaging) of the hands, as reported in a clinical trial within the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

1 Nov 2024

Drug repurposing offers hope for SYNGAP1 patients

The SynGAP Research Fund 501(c)(3) has awarded a pair of grants to Dr. Clement Chow, a geneticist and Associate Professor in the Department of Human Genetics at the University of Utah. These grants are crucial steps in advancing therapeutic development for SYNGAP1-Related Disorders (SRD).

30 Oct 2024

Clinical trial highlights efficacy of imlifidase for kidney transplant recipients

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX) - a procedure that removes antibodies from the plasma portion of the blood.

27 Oct 2024

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial.

27 Oct 2024

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful and sudden onset of swelling, sometimes resulting in death.

25 Oct 2024

Previous
1
...
7
8
9
10
11
12
13
...
1151
Next

Drug Trial News

CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis

Muvalaplin shows promise in lowering Lp(a) levels in clinical trial

New nasal spray form of bumetanide shows promise for heart failure treatment

Adding high-dose IV vitamin C to chemotherapy can boost survival for pancreatic cancer patients

Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

Daily tablet shows promise in treating achondroplasia in children

Tirzepatide improves heart health and function in obese HFpEF patients

New clinical trial offers hope for patients with rare immune disease IgG4-RD

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Phase 3 study finds inebilizumab effective for immunoglobulin G4–related disease

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

VANCE trial marks milestone in t cell therapy for solid tumors

Cleveland Clinic presents new findings on triple-negative breast cancer vaccine

Recruitment underway for a clinical trial testing new vaccine against respiratory viruses

Combination therapy shows promising results in treating stage 3 melanoma

Two topical treatments show similar benefits for photoaging of the hands

Drug repurposing offers hope for SYNGAP1 patients

Clinical trial highlights efficacy of imlifidase for kidney transplant recipients

Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Latest News